Fig. 2From: Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanomaBaseline serum levels of TGF-β1 and IL-10 correlate with progression free survival (PFS)Back to article page